This included inhibitors used in the treatment of depression (imipramine and atomoxetine) and attention-deficit hyperactivity disorder (atomoxetine), a smoking cessation agent (bupropion), a psychostimulant drug (cocaine), and pharmacological tool compounds with selectivity for NET (nisoxetine and talopram) or DAT (GBR 12,909, JHW 007 and rimcazole). This evidence concerns the gene SLC6A2 and depressive disorder.